Stem cell therapy for COVID-19 treatment: an umbrella review

Chaozhi Tang; Arkadiusz Dziedzic; Mahalaqua Nazli Khatib; Saad Alhumaid; Lakshmi Thangavelu; R. P. Parameswari; Prakasini Satapathy; Quazi Syed Zahiruddin; Sarvesh Rustagi; Maha Afri Alanazi; Majid S. Al-Thaqafy; Ali Hazazi; Jawaher Alotaibi; Nehad J. Al Faraj; Nisreen A. Al-Zaki; Mona J. Al Marshood; Thuria Y. Al Saffar; Khadija A. Alsultan; Shamsah H. Al-Ahmed; Ali A. Rabaan

doi:10.1097/JS9.0000000000001786

Stem cell therapy for COVID-19 treatment: an umbrella review

Chaozhi Tang
, Arkadiusz Dziedzic
, Mahalaqua Nazli Khatib
, Saad Alhumaid
, Lakshmi Thangavelu
, R. P. Parameswari
, Prakasini Satapathy
, Quazi Syed Zahiruddin
, Sarvesh Rustagi
, Maha Afri Alanazi
, Majid S. Al-Thaqafy
, Ali Hazazi
, Jawaher Alotaibi
, Nehad J. Al Faraj
, Nisreen A. Al-Zaki
, Mona J. Al Marshood
, Thuria Y. Al Saffar
, Khadija A. Alsultan
, Shamsah H. Al-Ahmed
, Ali A. Rabaan

Henan Normal University
Medical University of Silesia in Katowice
Datta Meghe Institute of Medical Sciences
University of Tasmania
Saveetha Institute of Medical and Technical Sciences (Deemed to be University)
Al-Mustaqbal University College
Uttaranchal University
Research Center
Ministry of National Guard Health Affairs
King Saud bin Abdulaziz University for Health Sciences
Security Forces Hospital Program Riyadh
Alfaisal University
King Faisal Specialist Hospital and Research Centre
Qatif Central Hospital
Johns Hopkins Aramco Healthcare
The University of Haripur

Research output: Contribution to journal › Review article › peer-review

3 Scopus citations

Abstract

BACKGROUND: COVID-19 has presented significant obstacles to healthcare. Stem cell therapy, particularly mesenchymal stem cells, has emerged as a potential treatment modality due to its immunomodulatory and regenerative properties. This umbrella review aims to synthesize current evidence from systematic reviews on the safety and efficacy of stem cell therapy in COVID-19 treatment. METHODS: A thorough literature search was performed across Embase, PubMed, Cochrane, and Web of Science from December 2019 to February 2024. Systematic reviews focusing on the use of stem cell therapy for COVID-19 were included. Evidence was synthesized by meta-analysis using R software (V 4.3) for each outcome. The certainty of evidence was assessed using the GRADE approach. RESULTS: A total of 24 systematic reviews were included. Stem cell therapy was associated with reduced mortality [risk ratio (RR) 0.72, 95% CI: 0.60-0.86]; shorter hospital stays (mean difference -4.00 days, 95% CI: -4.68 to -3.32), and decreased need for invasive ventilation (RR 0.521, 95% CI: 0.320-0.847). Symptom remission rates improved (RR 1.151, 95% CI: 0.998-1.330), and a reduction in C-reactive protein levels was noted (standardized mean difference -1.198, 95% CI: -2.591 to 0.195), albeit with high heterogeneity. For adverse events, no significant differences were found between stem cell therapy and standard care (RR 0.87, 95% CI: 0.607-1.265). The certainty of evidence ranged from low to moderate. CONCLUSION: Stem cell therapy demonstrates a potential benefit in treating COVID-19, particularly in reducing mortality and hospital stay duration. Despite these promising findings, the evidence is varied, and future large-scale randomized trials are essential to confirm the efficacy and optimize the therapeutic protocols for stem cell therapy in the management of the disease. The safety profile is encouraging, with no significant increase in adverse events, suggesting a viable avenue for treatment expansion.

Original language	English
Pages (from-to)	6402-6417
Number of pages	16
Journal	International Journal of Surgery
Volume	110
Issue number	10
DOIs	https://doi.org/10.1097/JS9.0000000000001786
State	Published - 1 Oct 2024
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1097/JS9.0000000000001786

Cite this

Tang, C., Dziedzic, A., Khatib, M. N., Alhumaid, S., Thangavelu, L., Parameswari, R. P., Satapathy, P., Zahiruddin, Q. S., Rustagi, S., Alanazi, M. A., Al-Thaqafy, M. S., Hazazi, A., Alotaibi, J., Al Faraj, N. J., Al-Zaki, N. A., Al Marshood, M. J., Al Saffar, T. Y., Alsultan, K. A., Al-Ahmed, S. H., & Rabaan, A. A. (2024). Stem cell therapy for COVID-19 treatment: an umbrella review. International Journal of Surgery, 110(10), 6402-6417. https://doi.org/10.1097/JS9.0000000000001786

@article{ec9df190f9ab4b66b8dc30765e76d32c,

title = "Stem cell therapy for COVID-19 treatment: an umbrella review",

abstract = "BACKGROUND: COVID-19 has presented significant obstacles to healthcare. Stem cell therapy, particularly mesenchymal stem cells, has emerged as a potential treatment modality due to its immunomodulatory and regenerative properties. This umbrella review aims to synthesize current evidence from systematic reviews on the safety and efficacy of stem cell therapy in COVID-19 treatment. METHODS: A thorough literature search was performed across Embase, PubMed, Cochrane, and Web of Science from December 2019 to February 2024. Systematic reviews focusing on the use of stem cell therapy for COVID-19 were included. Evidence was synthesized by meta-analysis using R software (V 4.3) for each outcome. The certainty of evidence was assessed using the GRADE approach. RESULTS: A total of 24 systematic reviews were included. Stem cell therapy was associated with reduced mortality [risk ratio (RR) 0.72, 95\% CI: 0.60-0.86]; shorter hospital stays (mean difference -4.00 days, 95\% CI: -4.68 to -3.32), and decreased need for invasive ventilation (RR 0.521, 95\% CI: 0.320-0.847). Symptom remission rates improved (RR 1.151, 95\% CI: 0.998-1.330), and a reduction in C-reactive protein levels was noted (standardized mean difference -1.198, 95\% CI: -2.591 to 0.195), albeit with high heterogeneity. For adverse events, no significant differences were found between stem cell therapy and standard care (RR 0.87, 95\% CI: 0.607-1.265). The certainty of evidence ranged from low to moderate. CONCLUSION: Stem cell therapy demonstrates a potential benefit in treating COVID-19, particularly in reducing mortality and hospital stay duration. Despite these promising findings, the evidence is varied, and future large-scale randomized trials are essential to confirm the efficacy and optimize the therapeutic protocols for stem cell therapy in the management of the disease. The safety profile is encouraging, with no significant increase in adverse events, suggesting a viable avenue for treatment expansion.",

author = "Chaozhi Tang and Arkadiusz Dziedzic and Khatib, \{Mahalaqua Nazli\} and Saad Alhumaid and Lakshmi Thangavelu and Parameswari, \{R. P.\} and Prakasini Satapathy and Zahiruddin, \{Quazi Syed\} and Sarvesh Rustagi and Alanazi, \{Maha Afri\} and Al-Thaqafy, \{Majid S.\} and Ali Hazazi and Jawaher Alotaibi and \{Al Faraj\}, \{Nehad J.\} and Al-Zaki, \{Nisreen A.\} and \{Al Marshood\}, \{Mona J.\} and \{Al Saffar\}, \{Thuria Y.\} and Alsultan, \{Khadija A.\} and Al-Ahmed, \{Shamsah H.\} and Rabaan, \{Ali A.\}",

note = "Publisher Copyright: Copyright {\textcopyright} 2024 The Author(s). Published by Wolters Kluwer Health, Inc.",

year = "2024",

month = oct,

day = "1",

doi = "10.1097/JS9.0000000000001786",

language = "English",

volume = "110",

pages = "6402--6417",

journal = "International Journal of Surgery",

issn = "1743-9191",

publisher = "Wolters Kluwer Health Inc",

number = "10",

}

Tang, C, Dziedzic, A, Khatib, MN, Alhumaid, S, Thangavelu, L, Parameswari, RP, Satapathy, P, Zahiruddin, QS, Rustagi, S, Alanazi, MA, Al-Thaqafy, MS, Hazazi, A, Alotaibi, J, Al Faraj, NJ, Al-Zaki, NA, Al Marshood, MJ, Al Saffar, TY, Alsultan, KA, Al-Ahmed, SH & Rabaan, AA 2024, 'Stem cell therapy for COVID-19 treatment: an umbrella review', International Journal of Surgery, vol. 110, no. 10, pp. 6402-6417. https://doi.org/10.1097/JS9.0000000000001786

TY - JOUR

T1 - Stem cell therapy for COVID-19 treatment

T2 - an umbrella review

AU - Tang, Chaozhi

AU - Dziedzic, Arkadiusz

AU - Khatib, Mahalaqua Nazli

AU - Alhumaid, Saad

AU - Thangavelu, Lakshmi

AU - Parameswari, R. P.

AU - Satapathy, Prakasini

AU - Zahiruddin, Quazi Syed

AU - Rustagi, Sarvesh

AU - Alanazi, Maha Afri

AU - Al-Thaqafy, Majid S.

AU - Hazazi, Ali

AU - Alotaibi, Jawaher

AU - Al Faraj, Nehad J.

AU - Al-Zaki, Nisreen A.

AU - Al Marshood, Mona J.

AU - Al Saffar, Thuria Y.

AU - Alsultan, Khadija A.

AU - Al-Ahmed, Shamsah H.

AU - Rabaan, Ali A.

PY - 2024/10/1

Y1 - 2024/10/1

N2 - BACKGROUND: COVID-19 has presented significant obstacles to healthcare. Stem cell therapy, particularly mesenchymal stem cells, has emerged as a potential treatment modality due to its immunomodulatory and regenerative properties. This umbrella review aims to synthesize current evidence from systematic reviews on the safety and efficacy of stem cell therapy in COVID-19 treatment. METHODS: A thorough literature search was performed across Embase, PubMed, Cochrane, and Web of Science from December 2019 to February 2024. Systematic reviews focusing on the use of stem cell therapy for COVID-19 were included. Evidence was synthesized by meta-analysis using R software (V 4.3) for each outcome. The certainty of evidence was assessed using the GRADE approach. RESULTS: A total of 24 systematic reviews were included. Stem cell therapy was associated with reduced mortality [risk ratio (RR) 0.72, 95% CI: 0.60-0.86]; shorter hospital stays (mean difference -4.00 days, 95% CI: -4.68 to -3.32), and decreased need for invasive ventilation (RR 0.521, 95% CI: 0.320-0.847). Symptom remission rates improved (RR 1.151, 95% CI: 0.998-1.330), and a reduction in C-reactive protein levels was noted (standardized mean difference -1.198, 95% CI: -2.591 to 0.195), albeit with high heterogeneity. For adverse events, no significant differences were found between stem cell therapy and standard care (RR 0.87, 95% CI: 0.607-1.265). The certainty of evidence ranged from low to moderate. CONCLUSION: Stem cell therapy demonstrates a potential benefit in treating COVID-19, particularly in reducing mortality and hospital stay duration. Despite these promising findings, the evidence is varied, and future large-scale randomized trials are essential to confirm the efficacy and optimize the therapeutic protocols for stem cell therapy in the management of the disease. The safety profile is encouraging, with no significant increase in adverse events, suggesting a viable avenue for treatment expansion.

AB - BACKGROUND: COVID-19 has presented significant obstacles to healthcare. Stem cell therapy, particularly mesenchymal stem cells, has emerged as a potential treatment modality due to its immunomodulatory and regenerative properties. This umbrella review aims to synthesize current evidence from systematic reviews on the safety and efficacy of stem cell therapy in COVID-19 treatment. METHODS: A thorough literature search was performed across Embase, PubMed, Cochrane, and Web of Science from December 2019 to February 2024. Systematic reviews focusing on the use of stem cell therapy for COVID-19 were included. Evidence was synthesized by meta-analysis using R software (V 4.3) for each outcome. The certainty of evidence was assessed using the GRADE approach. RESULTS: A total of 24 systematic reviews were included. Stem cell therapy was associated with reduced mortality [risk ratio (RR) 0.72, 95% CI: 0.60-0.86]; shorter hospital stays (mean difference -4.00 days, 95% CI: -4.68 to -3.32), and decreased need for invasive ventilation (RR 0.521, 95% CI: 0.320-0.847). Symptom remission rates improved (RR 1.151, 95% CI: 0.998-1.330), and a reduction in C-reactive protein levels was noted (standardized mean difference -1.198, 95% CI: -2.591 to 0.195), albeit with high heterogeneity. For adverse events, no significant differences were found between stem cell therapy and standard care (RR 0.87, 95% CI: 0.607-1.265). The certainty of evidence ranged from low to moderate. CONCLUSION: Stem cell therapy demonstrates a potential benefit in treating COVID-19, particularly in reducing mortality and hospital stay duration. Despite these promising findings, the evidence is varied, and future large-scale randomized trials are essential to confirm the efficacy and optimize the therapeutic protocols for stem cell therapy in the management of the disease. The safety profile is encouraging, with no significant increase in adverse events, suggesting a viable avenue for treatment expansion.

UR - https://www.scopus.com/pages/publications/85213596967

U2 - 10.1097/JS9.0000000000001786

DO - 10.1097/JS9.0000000000001786

M3 - Review article

C2 - 38967503

AN - SCOPUS:85213596967

SN - 1743-9191

VL - 110

SP - 6402

EP - 6417

JO - International Journal of Surgery

JF - International Journal of Surgery

IS - 10

ER -

Stem cell therapy for COVID-19 treatment: an umbrella review

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this